Cipla launches novel ‘5 in 1’ anti-ageing skin care product ‘Cutisera’

03 Dec 2015 Evaluate

Cipla, a global pharmaceutical company, has launched a novel ‘5 in 1’ anti-ageing skin care product ‘Cutisera’ developed by Stempeutics. Cutisera has been developed using bio-active factors derived from human adult stem cells to enhance the rejuvenation of ageing skin. The active ingredients have been tested for in vitro and in vivo efficacy. The product has been dermatologically tested with human volunteers with features of ageing skin over a period of 3 months, wherein the product was applied twice a day. This human study has demonstrated Cutisera’s effectiveness as a powerful and yet soothing anti-ageing skin care product suitable for all skin types of Indian origin. The formulated product does not contain any stem cells.

Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Its portfolio includes 1500 plus products across therapeutic categories with one quality standard globally.

Cipla Share Price

1565.50 22.05 (1.43%)
14-Jun-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1515.00
Dr. Reddys Lab 6080.25
Cipla 1565.50
Zydus Lifesciences 1110.95
Lupin 1601.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.